Virax Biolabs Group Limited (VRAX) is a Biotechnology company in the Healthcare sector, currently trading at $0.15. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is VRAX = $1 (+568% upside).
Valuation: VRAX trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25).
Financials: revenue is $6,331, +815.6%/yr average growth. Net income is $6M (loss), growing at -77.6%/yr. Net profit margin is -95739.2% (negative). Gross margin is -838.2% (-822.3 pp trend).
Balance sheet: total debt is $377,004 against $6M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 7.27 (strong liquidity). Debt-to-assets is 5.9%. Total assets: $6M.
Analyst outlook: 1 / 1 analysts rate VRAX as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
